Abstract
There is an incentive to functionalise hydroxyapatite (HA) for orthopaedic implant use
with bioactive agents to encourage superior integration of the implants into host bone.
One such agent is (3S) 1-fluoro-3-hydroxy-4-(oleoyloxy) butyl- 1-phosphonate (FHBP),
a phosphatase-resistant lysophosphatidic acid (LPA) analogue. We investigated the
effect of an FHBP-HA coating on the maturation of human (MG63) osteoblast-like cells.
Optimal coating conditions were identified and cell maturation on modified and
unmodified, control HA surfaces was assessed. Stress tests were performed to
evaluate coating survivorship after exposure to mechanical and thermal insults that
are routinely encountered in the clinical environment. MG63 maturation was found to
be 3 times greater on FHBP-modified HA compared to controls (p <0.0001). There was
no significant loss of coating bioactivity after autoclaving (P= 0.9813) although
functionality declined by 67% after mechanical cleaning and reuse (p<0.0001). The
bioactivity of modified disks was significantly greater than that of controls following
storage for up to 6 months (p<0.001). Herein we demonstrate that HA can be
functionalised with FHBP in a facile, scalable manner and that this novel surface has
the capacity to enhance osteoblast maturation. Improving the biological performance of
HA in a bone regenerative setting could be realised through the simple conjugation of
bioactive LPA species in the future.
Original language | English |
---|---|
Article number | 122 |
Number of pages | 10 |
Journal | Journal of Materials Science: Materials in Medicine |
Volume | 29 |
Issue number | 8 |
Early online date | 21 Jul 2018 |
DOIs | |
Publication status | Published - Aug 2018 |
Research Groups and Themes
- Centre for Surgical Research
Keywords
- Hydroxyapatite
- Lysophosphatidic acid
- Biomaterial functionalisation
- Bone graft
- vitamin D